Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.

The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.

Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.

The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.

January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.